Response to letter - Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists
- PMID: 28756060
- DOI: 10.1016/j.ejca.2017.06.042
Response to letter - Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists
Comment on
-
Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.Eur J Cancer. 2017 May;77:99-108. doi: 10.1016/j.ejca.2017.03.002. Epub 2017 Apr 5. Eur J Cancer. 2017. PMID: 28390298
-
Re: Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists.Eur J Cancer. 2017 Dec;87:203. doi: 10.1016/j.ejca.2017.06.041. Epub 2017 Sep 23. Eur J Cancer. 2017. PMID: 28947070 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical